jnj-37822681
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT01812642)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Fc1ccc(CN2CCC(Nc3ccc(C(F)(F)F)nn3)CC2)cc1F- Mol. weight
- 372.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3234237 ↗
Also known as
- jnj-37822681
- jnj-37822681
- jnj-37822681
- jnj-37822681
- n-(1-(3,4-difluorobenzyl)piperidin-4-yl)-6-(trifluoromethyl)pyridazin-3-amine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00728195 | Phase 2 | Nov 1, 2008 | Johnson and Johnson |
| NCT01812642 | Phase 2 | Jul 1, 2008 | Johnson and Johnson |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 2 | 2 | 1 | 2008 |
1 organizations
Page 1 / 1